Publication | Open Access

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Breast OncologyOncologyEngineeringOncologic ImagingCancer DetectionMedicineZephir TrialMolecular ImagingBreast ImagingBreast CancerCancer TreatmentMolecular DiagnosticsRadiation OncologyTumor MicroenvironmentTrastuzumab EmtansineRadiology